Vanguard Group Inc. Buys 163,556 Shares of Medtronic PLC $MDT

Vanguard Group Inc. grew its stake in Medtronic PLC (NYSE:MDT) by 0.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 127,072,962 shares of the medical technology company’s stock after acquiring an additional 163,556 shares during the period. Vanguard Group Inc. owned 9.91% of Medtronic worth $12,102,429,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of MDT. AXQ Capital LP raised its stake in shares of Medtronic by 25.6% in the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after purchasing an additional 2,013 shares during the period. UMB Bank n.a. grew its holdings in shares of Medtronic by 65.8% during the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after buying an additional 54,898 shares in the last quarter. Applied Finance Capital Management LLC acquired a new stake in Medtronic in the 3rd quarter valued at approximately $1,308,000. Principal Financial Group Inc. lifted its stake in Medtronic by 17.2% in the 3rd quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock valued at $157,732,000 after acquiring an additional 242,910 shares in the last quarter. Finally, Willis Investment Counsel boosted its position in Medtronic by 5.0% during the 3rd quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock worth $38,274,000 after acquiring an additional 19,192 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA cleared Medtronic’s Stealth AXiS system — an integrated planning, navigation and robotics platform for spine surgery that expands the company’s procedural addressable market and supports hardware/software recurring revenue potential. This is a material product‑launch catalyst for spine and future cranial/ENT applications. PR Newswire
• Positive Sentiment: Independent coverage and price‑target lifts: Barclays initiated coverage with an Overweight and $116 PT, and Needham upgraded to Buy with a $121 PT — both signal analyst conviction that recent product momentum and margins support upside from current levels. Benzinga Needham Upgrade
• Positive Sentiment: Market commentary highlights improving returns/operational momentum that could support multiple expansion if sustained — a constructive narrative for longer‑term investors. Yahoo Finance
• Neutral Sentiment: Q3 FY2026 earnings preview: analysts outline what to watch in the upcoming report (revenue cadence, procedure volumes, and guidance) — an event that could be a short‑term catalyst but not new information. MSN Earnings Preview
• Neutral Sentiment: Dividend/income writeups underscore MDT’s ~2.8% yield and ways to generate cash flow; supportive for income investors but a limited driver of near‑term price moves. Benzinga Dividend
• Negative Sentiment: Geopolitical and China exposure risks: analysis highlights tariffs and China’s volume‑based procurement (VBP) program as potential headwinds to margins and growth in a key market — a meaningful downside risk that can compress near‑term revenue and investor sentiment. Seeking Alpha

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Royal Bank Of Canada raised their target price on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. UBS Group restated a “neutral” rating and issued a $104.00 price objective on shares of Medtronic in a report on Wednesday, February 4th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $111.21.

Medtronic Trading Down 1.3%

Shares of NYSE:MDT opened at $99.57 on Monday. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a market capitalization of $127.65 billion, a P/E ratio of 26.84, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71. The company has a 50-day simple moving average of $99.28 and a 200 day simple moving average of $96.46.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).